🧾 What This Document Is

This is a Form 6-K, a monthly report GSK files with the U.S. SEC as a foreign company. Think of it as a "news bulletin" update for investors. This specific filing contains one major announcement: the regulatory approval of a new drug in China.

👉 Why it matters: For investors, this is a signal of successful commercial expansion into a huge market, which can drive future revenue growth.

🏢 What The Company Does

In simple terms, GSK is a giant global pharmaceutical and biotechnology company. They research, develop, and sell medicines, vaccines, and consumer health products. They are a major player in respiratory diseases (like asthma and COPD), infectious diseases, and oncology.

👉 This approval strengthens their core respiratory portfolio in a critical market.

🚀 The Big News: China Approval

The headline is that China's regulator, the National Medical Products Administration (NMPA), has approved Exdensur (depemokimab) for a specific type of severe asthma.

What is Exdensur? It's a biologic medicine (a complex drug made from living cells) that targets a key driver of inflammation. Its superpower is being ultra-long-acting—patients only need two doses per year.

👉 Why it matters: This infrequent dosing could be a major advantage for patient compliance and quality of life compared to more frequent injections.

📊 The Proof: Clinical Trial Results

The approval was based on two major Phase III clinical trials called SWIFT-1 and SWIFT-2. Here’s what they showed for patients with severe, eosinophilic (high white blood cell count) asthma:

• Dramatically Fewer Attacks: Patients on Exdensur had 58% and 48% fewer asthma attacks per year compared to placebo in the two trials.
• Fewer Hospitalizations: There was a 72% reduction in attacks severe enough to require a hospital or ER visit.
• Safety: The drug was well-tolerated, with side effects similar to placebo.

👉 Why it matters: These are strong efficacy numbers that demonstrate the drug's ability to prevent the most serious and costly outcomes of severe asthma.

🌍 Market Opportunity & Context

This approval opens up a massive market:

• 46 million adults in China have asthma.
• An estimated 6% of those (≈2.8 million people) have severe asthma.
• Severe asthma carries a high risk of dangerous attacks and hospitalization.

Exdensur is now the first and only biologic of its kind (ultra-long-acting) approved for this condition in China. It's already approved in the US, EU, UK, and Japan.

🔮 What's Next For Exdensur?

GSK isn't stopping here. The drug's potential is being tested in other diseases driven by the same type of inflammation:

• Already under review in China for severe chronic rhinosinusitis with nasal polyps (CRSwNP).
• Phase III trials are ongoing for conditions like Eosinophilic Granulomatosis with Polyangiitis (EGPA), Hyper-Eosinophilic Syndrome (HES), and Chronic Obstructive Pulmonary Disease (COPD).

👉 Why it matters: Success in these additional trials could significantly expand the drug's addressable patient population and revenue potential.

⚖️ Big Picture: Strengths & Risks

• 👍 Strengths: Fills a major unmet need in a large, growing market. Strong clinical data. Convenient dosing regimen. Extends GSK's leadership in respiratory medicine.
• ⚠️ Risks: Commercial success depends on market access, pricing negotiations in China, and competition from other asthma biologics. Future trial results in other diseases are not guaranteed.

🧠 The Analogy

Think of severe asthma like a house with a leaky pipe (type 2 inflammation) causing constant damage (exacerbations). Exdensur is like installing a super-efficient shut-off valve that only needs to be checked twice a year, preventing major floods (hospitalizations) and giving the homeowner (patient) major peace of mind.

📇 Key Contacts & People

Media Enquiries:

• Tim Foley: +44 (0) 20 8047 5502 (London)
• Sarah Clements: +44 (0) 20 8047 5502 (London)
• Kathleen Quinn: +1 202 603 5003 (Washington DC)
• Lyndsay Meyer: +1 202 604 5459 (Washington DC)

Investor Relations:

• Constantin Fest: +44 (0) 7831 826525 (London)
• James Dodwell: +44 (0) 20 8047 2406 (London)
• Mick Readey: +44 (0) 7990 339653 (London)
• Steph Mountifield: +44 (0) 7796 707505 (London)
• Sam Piper: +44 (0) 7824 52779 (London)
• Jeff McLaughlin: +1 215 751 7002 (Philadelphia)
• Frannie DeFranco: +1 215 751 3126 (Philadelphia)

Key Executive Quoted:

• Kaivan Khavandi, SVP, Global Head, Respiratory, Immunology & Inflammation R&D, GSK.

🧩 Final Takeaway

GSK has successfully launched its next-generation, twice-yearly severe asthma drug, Exdensur, in the world's most populous market. This is a significant commercial win that leverages their deep respiratory expertise and could provide a new, long-term revenue stream as they expand the drug's use into other diseases.